Live feed
·
INSIDERFilingvia Quantisnow
Channel Therapeutics Corporation logo

Large owner Ligand Pharmaceuticals Inc converted options into 1,500,000 shares (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
CHRO· Channel Therapeutics Corporation
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CHRO (Channel Therapeutics Corporation) and more on Quantisnow.